LKLubov V. Krepkova

Lubov V. Krepkova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lubov V. Krepkova has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ПАТРИМИН – СЕДАТИВНОЕ СРЕДСТВО ИЗ КОРНЕЙ ПАТРИНИИ СРЕДНЕЙ: АНАЛИЗ РЕЗУЛЬТАТОВ ЭКСПЕРИМЕНТАЛЬНОГО И КЛИНИЧЕСКОГО ИЗУЧЕНИЯ

    by Вера Викторовна Карабаева, Любовь Вениаминовна Крепкова, Екатерина Владимировна Ферубко, Александра Николаевна Бабенко, Ольга Николаевна Карабаева

    В лечении цереброваскулярных заболеваний наряду с нейропротекторами важно назначение препаратов, корректирующих психоэмоциональные расстройства и нарушения сна, в том числе созданных на основе лекарственного растительного сырья. Одним из таких препаратов является патримин – таблетки для приема внутрь, содержащие 100 мг сухого очищенного экстракта тритерпеновых гликозидов из корней патринии средней (Patrinia intermedia (Hornem.) Roem. & Schult. Целью настоящей работы явился анализ результатов экспериментального и клинического изучения патримина, проведенного в 1985–1992 годах по внутренним отчетам ВИЛАР и научным публикациям. Экспериментальные исследования выявили у патримина седативный, антигипертензивный, дезагрегационный эффекты. Патримин снижал уровень общего холестерина, триглицеридов и глюкозы в сыворотке крови экспериментальных животных. Клинические исследования патримина доказали его эффективность при хронической ишемии головного мозга, сопровождающейся нарушением психоэмоционального статуса, различными нарушениями сна, тревожностью. Сочетание мягкого седативного действия с наличием у патримина гипотензивного, гиполипидемического, антикоагулянтного, антиадгезивного эффектов сделало актуальным его применение у пациентов с цереброваскулярной патологией в сочетании с артериальной гипертонией, дислипидемией, ишемической болезнью сердца, особенно в гериатрической практике. In the treatment of cerebrovascular diseases, along with neuroprotectors, it is important to prescribe drugs that correct psychoemotional disorders and sleep disorders, including those based on medicinal herbal raw materials. One of these drugs is Patrimin, an oral tablet containing 100 mg of a dry purified extract of triterpene glycosides from the roots of Patrinia intermedia (Hornem.) Roem. & Schult. The aim of this work was to analyze the results of experimental and clinical studies of patrimin, conducted in 1985-1992, based on internal VILAR reports and scientific publications. Experimental studies have revealed sedative, antihypertensive, and disaggregative effects of patrimin. Patrimin reduced the levels of total cholesterol, triglycerides, and glucose in the blood serum of experimental animals. Clinical studies of patrimin have proven its effectiveness in treating chronic cerebral ischemia accompanied by emotional disturbances, sleep disorders, and anxiety. The combination of mild sedation with the presence of hypotensive, hypolipidemic, anticoagulant, and anti-adhesive effects of patrimin makes its use relevant in patients with cerebrovascular pathology in combination with arterial hypertension, dyslipidemia, and coronary heart disease, especially in geriatric practice.

  • Open Access

    Identification of luteolin-7-glucoside metabolites after oral administration and development of a method for their quantitative analysis

    by G. V. Adamov, О. Л. Сайбель, A. N. Babenko, Е. С. Мельников, A. I. Radimich, O. Yu. Kulyak, L. V. Krepkova, О. Ю. Куляк

    Introduction. The development and registration of antiviral drugs is an urgent task. Flavonoids, in particular, luteolin-7-glycoside (cinaroside, luteolin-7-O-glycoside) demonstrate high broad-spectrum antiviral activity in vitro, and the industrial regulations for the production of luteolin-7-glycoside from the leaves of holly willow have already been developed at the VILAR. One of the problems with the introduction of flavonoids into medical practice is their low bioavailability and intensive biotransformation. Existing publications provide contradictory data on the pharmacokinetics of luteolin-7-glycoside, and therefore our own research was conducted.Aim. To develop a methodology for the quantitative analysis of luteolin-7-glycoside and its metabolites in blood plasma and to test it on laboratory animals.Materials and methods. Animal experiments were carried out in accordance with the requirements of the "Guidelines for conducting preclinical studies of medicines". To develop a method of analysis and further clarify the time intervals of blood sampling, time points were analyzed: 30, 60 minutes, 2, 4, 8, 24 hours after administration of the test substance. Tubes with citrate blood of laboratory animals were centrifuged at 2000 rpm for 10 minutes. The plasma was placed in an Eppendorf-type test tube, frozen and stored at –20 °C until chromatographic analysis was performed. Blood plasma sample preparation was carried out by precipitation with methyl alcohol, the supernatant was chromatographically separated on a column Luna® 5 µm C18 column 100 Å 250 × 4.6 mm in a gradient mode in a water-acetonitrile system and a modifier – 0.2 % formic acid. The metabolites were identified by high-performance liquid chromatography with mass spectrometric detection. To do this, the spectral characteristics of the peaks that appeared on the chromatograms of blood plasma samples after oral administration of luteolin-7-glycoside were interpreted. The concentration of the analyzed substances was assessed by the internal standard method, which was rutin. To determine the concentration of luteolin, a standardized luteolin substance was used as a standard sample, the concentration of the remaining metabolites was estimated in terms of luteolin.Results and discussion. It was found that after oral administration of luteolin-7-glycoside in starch paste to laboratory animals, native luteolin-7-glycoside was not detected in blood plasma. The main metabolites were luteolin-diglucuronide and luteolin-glucuronide, their maximum plasma concentrations are about three times higher than luteolin and methyllyuteolin-diglucuronide. The results are compared with data from other studies.Conclusion. The absence of native luteolin-7-glycoside in blood plasma after oral administration makes it necessary to seriously reconsider the relevance of the conclusions obtained during studies of its activity in vitro. However, in the presence of antiviral activity in vivo, there is an urgent need for further research to establish the real mechanisms of action of this medicinal substance.

  • Open Access

    Retrospective Analysis of Experimental and Clinical Studies of Flakozid in Viral Hepatitis

    by V. V. Karabaeva, L. V. Krepkova, A. N. Babenko, V. V. Bortnikova, T. V. Fateeva, P. G. Mizina, N. S. Mikheeva, O. N. Karabaeva

    Introduction. Viral hepatitis (HV) by its socio-economic significance occupies one of the leading places in human infectious pathology, therefore, the development of fundamentally new methods of prevention, diagnosis and treatment, as well as the creation of new antiviral drugs remain relevant. An antiviral herbal drug "Flakozid" has been created in VILAR, which is presented in a dosage form – 0,1 g tablets for oral administration.Аim. To analyze the experimental and clinical efficacy and safety of flakozid therapy in viral hepatitis.Materials and methods. Experimental study of the effect of flakozid on viral hepatitis A (HAV). The AGMK cell culture (BS-C-1 line) and the hepatitis A virus strain HM 175 adapted to it were used in the work. The studies were conducted in two series of experiments using different concentrations of the drug, which was introduced into cultures simultaneously with the infection of HAV. Experimental study of the effect of flakozid on viral hepatitis C (HCV). In the present experiments, a virus-containing culture fluid collected from infected cultures of chicken embryo fibroblasts containing 7,0 lg TCD50/ml of infectious HCV (genotype 1b) was used. The cytotoxic, viricidal and antiviral activity of flakozid was studied using transplanted cultures of pig embryo kidney cells (SPEV) obtained from the collection of cell lines of the D. I. Ivanovsky Research institute of virology of the Ministry of Health of the Russian Federation. In the experiments, a one-day monolayer of cells grown in 96-well plastic culture panels was used. ID50 – the concentration of the drug "Flacozid", which inhibits the development of the virus in the monolayer by 50 %, and CD50 – its minimum concentration, which causes cytotoxic destruction of 50 % of the cells of the monolayer, as well as the CTI – chemotherapeutic index, calculated as the ratio of CD50 to ID50, were determined. A well – known domestic antiviral agent, "Ribavirin", was used as a comparison drug. Clinical studies of flakozid in viral hepatitis A. The results of clinical studies of the antiviral drug "Flakozid" (0,1 g tablets) were analyzed in 258 patients with viral hepatitis A. "Flakozid" was prescribed to patients with a moderate course of the disease, 0,1 g 3 times a day for 20 days against the background of basic therapy: diet, alkaline drinking, Enterodes®. The therapeutic effect was assessed by clinical (weakness, decreased appetite, nausea, vomiting) and biochemical parameters (the level of direct bilirubin, transaminase activity), as well as by the severity of hepatolienal syndrome. Clinical studies of flakozid in viral hepatitis В. The results of clinical studies of the antiviral drug "Flakozid"(0,1 g tablets) were analyzed in 410 patients with acute viral hepatitis B, which was regarded as moderate. "Flakozid" was prescribed against the background of basic therapy: diet and detoxification therapy: 5 % glucose solution, 5 % ascorbic acid solution, "Hemodesi", at a daily dose of 0,3–0,8 g for up to 38 days. The comparison group received the same basic therapy without flakozid. The dynamics of clinical symptoms (general weakness, headache, sleep disorders, dizziness, nausea, vomiting, impaired appetite, itchy skin, pain in the right hypochondrium, jaundice, etc.), data from laboratory examination methods were evaluated, markers of hepatitis B – HBeAg and Australian antigen (HBsAg) were determined every 10 days and indicators of cellular immunity before the appointment and after 21 days of treatment; the absolute number of lymphocytes, the total number of T-lymphocytes, as well as theophylline-resistant and theophylline-sensitive cells.Results and discussion. The results of experimental studies revealed the antiviral effect of flakozid against the hepatitis A virus, confirmed during clinical studies in adult patients. Treatment with flakozid in patients with viral hepatitis A against the background of basic therapy at a daily dose of 0,3 g for 20 days led to a significant reduction in the symptoms of intoxication, a reduction in the jaundice period, normalization of the size of the liver and spleen. Treatment with flakozid as part of complex therapy of patients with acute viral hepatitis B (AHVB) of moderate severity in daily doses of 0,3–0,8 g for 38 days showed its high effectiveness, contributing to a faster disappearance of clinical symptoms of the disease (improvement of the general condition of patients, reduction of the severity and disappearance of clinical symptoms of intoxication, reducing of the jaundice period), normalization of biochemical parameters (reducing the level of bilirubin and transaminase activity), as well as elimination of HBsAg from the blood, stimulation of cellular immunity. "Flakozid" was well tolerated, did not cause allergic reactions. Based on the results of clinical studies, "Flakozid" is approved for medical use as an antiviral agent (registration number 90/248/7). The high antiviral activity of flakozid against the hepatitis C virus in cell cultures was established. In terms of the severity of the therapeutic effect, "Flakozid" was not inferior to ribavirin, and in terms of CTI it was noticeably superior.Conclusion. Treatment with flakozid in patients with viral hepatitis A and B showed its high efficiency, contributed to a faster disappearance of clinical symptoms of the disease, normalization of biochemical parameters, elimination of HCV from the blood, good tolerability. "Flakozid" is recommended in clinical practice in the complex treatment of hepatitis A and B. In vitro experiments have established a high antiviral activity of flakozid against the hepatitis C virus, which justifies the possibility of conducting clinical studies of the drug in patients with the viral hepatitis C.


  • Open Access

    A Retrospective Analysis of the Clinical Studies of a Drug "Flakozid" in the Treatment of Diseases of the Hepatobiliary System

    by V. V. Bortnikova, V. V. Karabaeva, L. V. Krepkova, P. G. Mizina, A. N. Babenko, N. S. Mikheeva, O. N. Karabaeva

    Introduction. The medicine "Flakozid" with hepatoprotective effect has been developed at the VILAR. The drug is presented in dosage form-tablets of 0.1 g for oral drug administrationAim. To analyze the clinical efficacy and safety of "Flakozid" therapy according to clinical laboratory methods, as well as the motility of the gallbladder and bile ducts in patients with diseases of the hepatobiliary system.Materials and methods. The results of clinical studies of "Flakozid" (0.1 g tablets) were analyzed in 99 patients with chronic active hepatitis, chronic stone-free cholecystitis and fatty liver dystrophy, conducted in 2 clinical institutions: Perm State Medical University. Academician E. A. Wagner of the Ministry of Health of Russia and the Central Research Institute of Gastroenterology. "Flakozid" was prescribed against the background of a therapeutic diet (Table No. 5) of 0.1-0.2 g 3 times a day after meals for 32 days and repeated courses (3-5) for 6-12 months. Analysis of the efficacy and safety of "Flakozid" was carried out on the basis of the results of clinical and laboratory studies: general and biochemical blood analysis, general urinalysis, electrocardiogram. To study the motility of the gallbladder and biliary tract, the method of multifractional duodenal probing was used to determine the functional state of the sphincter apparatus of the gallbladder and biliary tract. In cystic and hepatic bile, its biochemical composition was determined. All patients underwent X-ray examination of the gastrointestinal tract, liver scanning and hepatography with iodine-131-bengal-roz.Results and discussion. In chronic active hepatitis, chronic stone-free cholecystitis and fatty liver dystrophy the use of "Flakozid" orally in daily doses of 0.3-0.6 g for 25-45 days led to an improvement in the General condition of patients, a decrease in pain in the right hypochondrium, a decrease in dyspeptic disorders, and an improvement in appetite. According to cholecystography, the indicators of concentration and contractility of the gallbladder improved. In terms of the severity of the therapeutic effect, "Flakozid" was not inferior to silibor and carsil, and in some indicators (improvement of the motility of the gallbladder and biliary tract) significantly exceeded them.Conclusions. Treatment of "Flakozid" improved functional state of the liver, reducing the syndrome of cytolysis and cholestasis. "Flakozid" is recommended in clinical practice in the complex treatment of diseases of the hepatobiliary system, such as chronic active hepatitis, chronic stone-free cholecystitis and fatty liver dystrophy.


  • Top Cited Papers
    Open Access

    Use of Herbal Medicine by Pregnant Women: What Physicians Need to Know

    by Sílvia M. Illamola, Ogochukwu U. Amaeze, Lubov V. Krepkova, Angela K. Birnbaum, Ashwin Karanam, Kathleen M. Job, Valentina V. Bortnikova, Catherine M.T. Sherwin, Elena Y. Enioutina

    About 80% of the consumers worldwide use herbal medicine (HMs) or other natural products. The percentage may vary significantly (7%–55%) among pregnant women, depending upon social status, ethnicity, and cultural traditions. This manuscript discusses the most common HMs used by pregnant women, and the potential interactions of HMs with conventional drugs in some medical conditions that occur during pregnancy (e.g., hypertension, asthma, epilepsy). It also includes an examination of the characteristics of pregnant HM consumers, the primary conditions for which HMs are taken, and a discussion related to the potential toxicity of HMs taken during pregnancy. Many cultures have used HMs in pregnancy to improve wellbeing of the mother and/or baby, or to help decrease nausea and vomiting, treat infection, ease gastrointestinal problems, prepare for labor, induce labor, or ease labor pains. One of the reasons why pregnant women use HMs is an assumption that HMs are safer than conventional medicine. However, for pregnant women with pre-existing conditions like epilepsy and asthma, supplementation of conventional treatment with HMs may further complicate their care. The use of HMs is frequently not reported to healthcare professionals. Providers are often not questioning HM use, despite little being known about the HM safety and HM-drug interactions during pregnancy. This lack of knowledge on potential toxicity and the ability to interact with conventional treatments may impact both mother and fetus. There is a need for education of women and their healthcare professionals to move away from the idea of HMs not being harmful. Healthcare professionals need to question women on whether they use any HMs or natural products during pregnancy, especially when conventional treatment is less efficient and/or adverse events have occurred as herbal-drug interactions could be the reason for these observations. Additionally, more preclinical and clinical studies are needed to evaluate HM efficacy and toxicity.


  • Experimental Study of Flakozid Activity in Viral Hepatitis C In Vitro

    by T. V. Fateeva, P. G. Deryabin, V. V. Bortnikova, L. V. Krepkova, P. G. Mizina

    Antiviral activity of a Russian drug flakozid towards infection caused by a cytopathogenic variant of hepatitis C virus in SPEV cells is studied. Flakozid is an individual natural flavonoid glycoside 7-O-β-D-glucopyranoside-8-(methyl-but)-2-enyl)-5,4’-dioxyflavanolol), isolated from the leaves of Phellodendron amurense Rupr. and Ph. amurense var. lavallei (Dode) Sprague, Rutaceae family. High antiviral activity of flakozid manifests in response to its addition into the monolayer of SPEV cells infected by hepatitis C virus during all periods of experiment. Flakozid exhibits weak cytotoxicity and no viricidal activity towards hepatitis C virus, which is comparable to activity of ribavirin (antiviral drug). Chemotherapeutic index of flakozid is 15-25 times higher than that of the reference drug ribavirin.


  • Влияние экстракта из травы зюзника европейского (Lycopus europaeus L.), обладающего тиреостатическим действием, на развитие потомства крыс в анте- и постнатальном периодах развития

    by Т. Б. Савинова, Л. В. Крепкова, А. Н. Бабенко, Валентина Васильевна Бортникова

    Изучено влияние сухого экстракта из травы зюзника европейского (Lycopus europaeus L.) экстракта сухого, обладающего тиреостатическим эффектом, на развитие потомства крыс. Показано, что изучаемый экстракт при введении в желудок крысам в течение всей беременности в виде водного раствора в дозах 50, 250 и 750 мг/кг не увеличивал эмбриональную смертность и не влиял на массу тела и краниокаудальный размер эмбрионов. В максимальной исследованной дозе зюзника экстракт нарушал процесс оссификации 20-дневных плодов, замедляя скорость окостенения хрящевых закладок костей. Зюзника экстракт сухой не влиял на выживаемость, динамику массы тела и формирование сенсорно-двигательных рефлексов крысят, но вызывал у них гипотрофию щитовидной железы при введении в максимальной изученной дозе.

  • Phytotherapy as an alternative to conventional antimicrobials: combating microbial resistance

    by Elena Yu. Enioutina, Lida Teng, Tatyana V. Fateeva, Jessica C.S. Brown, Kathleen M. Job, Valentina V. Bortnikova, Lubov V. Krepkova, Michael I. Gubarev, Catherine M.T. Sherwin

    Introduction: In the modern antimicrobial era, the rapid spread of resistance to antibiotics and introduction of new and mutating viruses is a global concern. Combating antimicrobial resistant microbes (AMR) requires coordinated international efforts that incorporate new conventional antibiotic development as well as development of alternative drugs with antimicrobial activity, management of existing antimicrobials, and rapid detection of AMR pathogens. Areas covered: This manuscript discusses some conventional strategies to control microbial resistance. The main purpose of the manuscript is to present information on specific herbal medicines that may serve as good treatment alternatives to conventional antimicrobials for infections sensitive to conventional as well as resistant strains of microorganisms. Expert commentary: Identification of potential new antimicrobials is challenging; however, one source for potential structurally diverse and complex antimicrobials are natural products. Natural products may have advantages over other post-germ theory antimicrobials. Many antimicrobial herbal medicines possess simultaneous antibacterial, antifungal, antiprotozoal and/or antiviral properties. Herbal products have the potential to boost host resistance to infections, particularly in immunocompromised patients. Antimicrobial broad-spectrum activity in conjunction with immunostimulatory properties may help to prevent microbial resistance to herbal medicine. As part of the efforts to broaden use of herbal medicines to treat microbial infections, pre-clinical and clinical testing guidelines of these compounds as a whole should be implemented to ensure consistency in formulation, efficacy and safety.


  • Исследование гепатопротекторного действия володушки экстракта сухого

    by Валентина Васильевна Бортникова, Любовь Вениаминовна Крепкова, Марина Аркадьевна Джавахян, П. Г. Мизина

    Изучение володушки золотистой (Bupleurum aureum Fisch. seu longifolium L.) экстракта сухого на крысах с экспериментальной моделью острой интоксикации сулемой показало, что исследуемый экстракт обладает гепатопротекторным действием в дозах 10 и 100 мг/кг. По степени выраженности гепатозащитного действия на указанной модели патологии печени володушки экстракт сухой в дозе 10 мг/кг несколько превосходил карсил, наиболее широко применяющийся в настоящее время в медицинской практике гепатопротектор.